BlackRock Finance, Inc. - ACADIA PHARMACEUTICALS INC ownership

ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 263 filers reported holding ACADIA PHARMACEUTICALS INC in Q2 2024. The put-call ratio across all filers is 0.36 and the average weighting 0.2%.

Quarter-by-quarter ownership
BlackRock Finance, Inc. ownership history of ACADIA PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2024$196,010,963
-9.2%
12,062,213
+3.4%
0.00%
-20.0%
Q1 2024$215,755,004
-39.6%
11,668,740
+2.3%
0.01%
-44.4%
Q4 2023$357,262,222
+70.9%
11,410,483
+13.8%
0.01%
+50.0%
Q3 2023$208,995,709
-13.1%
10,028,585
-0.1%
0.01%
-14.3%
Q2 2023$240,446,049
+29.5%
10,039,501
+1.7%
0.01%
+40.0%
Q1 2023$185,737,046
+13.7%
9,869,131
-3.8%
0.01%0.0%
Q4 2022$163,326,211
+0.1%
10,259,184
+2.9%
0.01%
-16.7%
Q3 2022$163,161,000
+18.9%
9,973,155
+2.4%
0.01%
+50.0%
Q2 2022$137,256,000
-43.2%
9,741,314
-2.3%
0.00%
-42.9%
Q1 2022$241,472,000
+2.8%
9,970,023
-0.9%
0.01%
+16.7%
Q4 2021$234,810,000
+39.2%
10,060,312
-0.9%
0.01%
+20.0%
Q3 2021$168,673,000
-31.8%
10,154,951
+0.2%
0.01%
-28.6%
Q2 2021$247,295,000
+29.5%
10,139,203
+37.0%
0.01%
+16.7%
Q1 2021$190,960,000
-50.6%
7,401,602
+2.4%
0.01%
-50.0%
Q4 2020$386,560,000
+30.9%
7,230,797
+1.0%
0.01%
+9.1%
Q3 2020$295,400,000
-21.4%
7,161,211
-7.7%
0.01%
-26.7%
Q2 2020$376,022,000
-12.2%
7,757,846
-23.5%
0.02%
-28.6%
Q1 2020$428,249,000
-2.2%
10,136,110
-1.0%
0.02%
+23.5%
Q4 2019$438,020,000
+27.7%
10,238,895
+7.4%
0.02%
+21.4%
Q3 2019$342,960,000
+32.9%
9,529,325
-1.3%
0.01%
+27.3%
Q2 2019$258,040,000
-10.3%
9,653,564
-9.9%
0.01%
-15.4%
Q1 2019$287,799,000
+75.6%
10,718,708
+5.8%
0.01%
+62.5%
Q4 2018$163,859,000
-19.4%
10,133,466
+3.5%
0.01%
-11.1%
Q3 2018$203,175,000
+36.7%
9,786,905
+0.5%
0.01%
+28.6%
Q2 2018$148,654,000
-0.5%
9,735,101
+46.4%
0.01%0.0%
Q1 2018$149,407,000
-26.1%
6,649,227
-0.9%
0.01%
-30.0%
Q4 2017$202,060,000
-16.0%
6,710,697
+5.0%
0.01%
-16.7%
Q3 2017$240,664,000
+54.3%
6,388,747
+14.3%
0.01%
+50.0%
Q2 2017$155,925,000
-16.5%
5,590,706
+2.9%
0.01%
-20.0%
Q1 2017$186,791,000
+6484.1%
5,433,209
+5422.8%
0.01%
+150.0%
Q4 2016$2,837,000
+562.9%
98,377
+630.3%
0.00%
+300.0%
Q3 2016$428,000
+6.7%
13,471
+8.8%
0.00%0.0%
Q2 2016$401,000
+163.8%
12,377
+128.6%
0.00%
Q1 2016$152,000
+87.7%
5,414
+139.5%
0.00%
Q4 2015$81,000
+42.1%
2,261
+31.5%
0.00%
Q3 2015$57,000
-33.7%
1,719
-16.4%
0.00%
Q2 2015$86,000
+26.5%
2,056
-1.1%
0.00%
Q1 2015$68,000
+3.0%
2,0780.0%0.00%
Q4 2014$66,000
+10.0%
2,078
-13.7%
0.00%
Q3 2014$60,000
+9.1%
2,4080.0%0.00%
Q2 2014$55,000
-9.8%
2,408
-4.1%
0.00%
Q1 2014$61,000
+3.4%
2,511
+6.2%
0.00%
Q4 2013$59,000
-9.2%
2,3640.0%0.00%
Q3 2013$65,000
-91.7%
2,364
-94.5%
0.00%
-100.0%
Q2 2013$784,00043,2410.00%
Other shareholders
ACADIA PHARMACEUTICALS INC shareholders Q2 2024
NameSharesValueWeighting ↓
Ally Bridge Group (NY) LLC 474,741$7,557,8777.35%
Finepoint Capital LP 1,176,830$18,7356.06%
Baker Brothers Advisors 41,923,486$667,421,8974.01%
Palo Alto Investors LP 2,376,369$37,831,7943.23%
EcoR1 Capital, LLC 5,991,479$95,384,3462.90%
Birchview Capital, LP 249,400$3,9702.80%
Bain Capital Life Sciences Investors, LLC 701,402$11,1661.25%
Ikarian Capital, LLC 325,000$5,174,0011.25%
RTW INVESTMENTS, LP 3,670,938$58,441,3331.19%
EMERALD MUTUAL FUND ADVISERS TRUST 1,048,750$16,696,1001.03%
View complete list of ACADIA PHARMACEUTICALS INC shareholders